Allogene Therapeutics (ALLO) Liabilities and Shareholders Equity (2018 - 2026)

Allogene Therapeutics (ALLO) has 9 years of Liabilities and Shareholders Equity data on file, last reported at $396.0 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity fell 22.05% year-over-year to $396.0 million; the trailing twelve-month figure through Mar 2026 stood at $1.7 billion (down 24.88% YoY), and the FY2025 full-year result was $415.9 million, down 24.2% from the prior year.
• Liabilities and Shareholders Equity slipped to $396.0 million in Q1 2026, from $415.9 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $978.1 million in Q1 2022 to a low of $396.0 million in Q1 2026.
• A 5-year average of $654.7 million and a median of $642.8 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• Peak annual rise in Liabilities and Shareholders Equity reached 13.37% in 2025, while the deepest fall reached 27.25% in 2025.
• Tracing ALLO's Liabilities and Shareholders Equity over 5 years: stood at $821.6 million in 2022, then retreated by 21.76% to $642.8 million in 2023, then declined by 14.64% to $548.7 million in 2024, then decreased by 24.2% to $415.9 million in 2025, then declined by 4.8% to $396.0 million in 2026.
• Business Quant data shows ALLO's Liabilities and Shareholders Equity at $396.0 million in Q1 2026, $415.9 million in Q4 2025, and $439.8 million in Q3 2025.